Davis KH, Asiimwe A, Zografos LJ, McSorley DJ, Andrews EB. Evaluation of risk-minimization activities for cyproterone acetate 2 mg/ethinylestradiol 35 μg: a cross-sectional physician survey. Pharmaceut Med. 2017 Oct;31(5):339-51. doi: 10.1007/s40290-017-0203-9
Barnett C, Auffenberg G, Cheng Z, Yang F, Wang J, Wei J, Miller D, Montie J. Can frequency of prostate biopsy on active surveillance be reduced without significantly increasing risk? Poster presented at the 112th American Urological Association Annual Meeting; May 2017. Boston, MA. [abstract] J Urol. 2017 Apr; 197(4 Supplement):e552-3. doi: 10.1016/j.juro.2017.02.1311